AFLD and NASH in HIV-patients, prevalence and risk factors.

• Conditions: fatty liver; liver steatosis; 10019654; 10047438

• Registration Number: NL-OMON46464
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 1000

Inclusion Criteria

Unselected adult HIV-infected patients visiting the outpatient clinic of a major HIV reference centers in the Netherland (Erasmus MC).

Exclusion Criteria

* Excessive alcohol consumption (> 5 glasses per day)
* (History of) hepatocellular carcinoma
* Liver transplant in the past
* Contraindications fibroscan (pregnancy, pacemaker)
* Other liver diseases (autoimmune hepatitis, hemochromatosis, Wilson's disease).
Note: Chronic hepatitis B and C are not exclusionary criteria.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Prevalence of NASH in our HIV-infected population compared to what is known<br /><br>from other HIV populations (6-11%).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>2. Risk factors for NASH<br /><br>3. Prevalence of NALFD in our HIV-infected population compared to what is known<br /><br>from other HIV populations (30-55%).<br /><br>4. Risk factors for NALFD</p><br>